Literature DB >> 16282091

Pharmacotherapy of comorbid mood, anxiety, and substance use disorders.

Kathleen T Brady1, Marcia L Verduin.   

Abstract

Mood and anxiety disorders commonly co-occur with substance use disorders. Exploration of the neurobiology of substance use disorders and mood and anxiety disorders have found that the neural circuitry in mood, anxiety, and substance use disorders is clearly overlapping. These discoveries have encouraged the exploration of a number of pharmacotherapeutic agents in the treatment of co-occurring mood, anxiety, and substance use disorders. In this article, recent data on the pharmacotherapeutic treatment of mood and anxiety disorders in individuals with substance use disorders are reviewed. Some of the barriers to the use of pharmacotherapy in individuals with substance use disorders are discussed.

Entities:  

Mesh:

Year:  2005        PMID: 16282091     DOI: 10.1080/10826080500294924

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  12 in total

Review 1.  Neurobiological processes in adolescent addictive disorders.

Authors:  Ty S Schepis; Bryon Adinoff; Uma Rao
Journal:  Am J Addict       Date:  2008 Jan-Feb

Review 2.  Was Hawan Designed to Fight Anxiety-Scientific Evidences?

Authors:  R K Romana; A Sharma; V Gupta; R Kaur; S Kumar; P Bansal
Journal:  J Relig Health       Date:  2020-02

Review 3.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

Review 4.  Treatment of co-occurring anxiety disorders and substance use disorders.

Authors:  R Kathryn McHugh
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

5.  The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys.

Authors:  Daniel F Manvich; Heather L Kimmel; Debra A Cooper; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-06-08       Impact factor: 4.030

6.  Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.

Authors:  Evan Kyzar; Adam Michael Stewart; Samuel Landsman; Christopher Collins; Michael Gebhardt; Kyle Robinson; Allan V Kalueff
Journal:  Brain Res       Date:  2013-07-01       Impact factor: 3.252

Review 7.  Exploring the comorbidity of anxiety and substance use disorders.

Authors:  Sonja Pasche
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

8.  Repeated stimulation of CRF receptors in the BNST of rats selectively induces social but not panic-like anxiety.

Authors:  Younglim Lee; Stephanie Fitz; Philip L Johnson; Anantha Shekhar
Journal:  Neuropsychopharmacology       Date:  2008-02-20       Impact factor: 7.853

9.  Enhanced sensitivity to naltrexone-induced drinking suppression of fluid intake and sucrose consumption in maternally separated rats.

Authors:  Clifford C Michaels; Stephen G Holtzman
Journal:  Pharmacol Biochem Behav       Date:  2007-03-28       Impact factor: 3.533

Review 10.  Integrated treatment of substance use and psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley
Journal:  Soc Work Public Health       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.